Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, PK/PD, and clinical effect of GSK2646264 in adults with cutaneous lupus erythematosus; trial completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• GSK2646264

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lupus Erythematosus, Cutaneous | Phase 1 | Status: COMPLETED | Results posted: 2019-07-26